Intellia Therapeutics (NTLA) reported a Q4 net loss Thursday of $1.27 per diluted share, narrower than a loss of $1.46 a year earlier.
Analysts polled by FactSet expected a loss of $1.33.
Collaboration revenue for the quarter ended Dec. 31 was $12.9 million, compared with a revenue loss of $1.9 million a year earlier.
Analysts surveyed by FactSet expected $8.6 million.
The company said it had cash, cash equivalents and marketable securities of $861.7 million as of Dec. 31, which is expected to fund operations into H1 2027.
Intellia shares were rising past 5% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。